60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
sxtp · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.43
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.43 | ↑ 0.03% |
1-day model range: $1.41–$1.45. Peak: $1.45 (+0.03%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · SXTP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-22 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-05-20 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-04-09 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-01-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-28 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-03 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-06-02 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-02-25 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on 60 Degrees Pharmaceuticals, Inc. (SXTP) stock. Of the recent 12 rating actions, 0 were upgrades and 1 were downgrades. 2 analysts currently cover SXTP.
Analyst Recommendation Trends
SXTP analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 33.3% YoY
Revenue Next Year
$1M
↑ 133.3% YoY
EPS This Year
$-107.68
EPS Next Year
$-11.74
↓ 89.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast SXTP EPS of $-107.68 for the current fiscal year, based on estimates from 1 analysts. The SXTP revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SXTP stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SXTP price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The SXTP short-term stock prediction for tomorrow is $1.43 (+0.03%).
60 Degrees Pharmaceuticals, Inc. trades on NASDAQ under the ticker SXTP. The SXTP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
SXTP forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month SXTP price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.43.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.